173 related articles for article (PubMed ID: 27614744)
1. A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.
Abdel-Razik A; Mousa N; Elalfy H; Sheta TF; Awad M; Abdelsalam M; Elhelaly R; Elzehery R; Gouda NS; Eldars W
J Gastrointest Cancer; 2017 Mar; 48(1):50-57. PubMed ID: 27614744
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and insulin-like growth factor-1 in differential diagnosis of ascites.
Abdel-Razik A; Eldars W; Elhelaly R; Elzehery R
J Gastroenterol Hepatol; 2016 Nov; 31(11):1868-1873. PubMed ID: 27010362
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of vascular endothelial growth factor in malignant ascites.
Zhan N; Dong WG; Wang J
Tumour Biol; 2016 Mar; 37(3):3719-25. PubMed ID: 26462841
[TBL] [Abstract][Full Text] [Related]
4. Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites.
Yildirim B; Sari R; Isci N
J Natl Med Assoc; 2005 Feb; 97(2):276-80. PubMed ID: 15712792
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.
Cheng D; Liang B; Kong H
Med Oncol; 2012 Jun; 29(2):1397-402. PubMed ID: 21556933
[TBL] [Abstract][Full Text] [Related]
6. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites.
Alexandrakis MG; Moschandrea J; Kyriakou DS; Alexandraki R; Kouroumalis E
Int J Biol Markers; 2001; 16(1):45-9. PubMed ID: 11288954
[TBL] [Abstract][Full Text] [Related]
7. Role of VEGF and CD44v6 in differentiating benign from malignant ascites.
Dong WG; Sun XM; Yu BP; Luo HS; Yu JP
World J Gastroenterol; 2003 Nov; 9(11):2596-600. PubMed ID: 14606105
[TBL] [Abstract][Full Text] [Related]
8. Significance of serum and ascitic fluid C-reactive protein in differential diagnosis of benign and malignant ascites.
Yuksel I; Karaahmet F; Coskun Y; Kılıncalp S; Hamamci M; Akinci H; Ustun Y; Simsek Z; Erarslan E; Coban S
Dig Dis Sci; 2014 Oct; 59(10):2588-93. PubMed ID: 24838501
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax.
Gu Y; Zhang M; Li GH; Gao JZ; Guo L; Qiao XJ; Wang LH; He L; Wang ML; Yan L; Fu XH
Chin Med J (Engl); 2015 Feb; 128(3):305-9. PubMed ID: 25635424
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites.
Sun J; Chang YX; Niu CY
Tumour Biol; 2017 Nov; 39(11):1010428317726840. PubMed ID: 29130388
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of detecting VEGF, CD44v6, MMP-2, and MMP-9 in malignant ascites].
Sun XM; Dong WG; Yu BP; Luo HS; Yu JP
Ai Zheng; 2004 Jan; 23(1):85-9. PubMed ID: 14720382
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of interferon gamma-induced protein 10 kDa in spontaneous bacterial peritonitis: single-center study.
Abdel-Razik A; Mousa N; Elbaz S; Eissa M; Elhelaly R; Eldars W
Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1087-93. PubMed ID: 26020377
[TBL] [Abstract][Full Text] [Related]
13. (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
Bala L; Sharma A; Yellapa RK; Roy R; Choudhuri G; Khetrapal CL
NMR Biomed; 2008 Jul; 21(6):606-14. PubMed ID: 18205245
[TBL] [Abstract][Full Text] [Related]
14. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
Tuzun Y; Yilmaz S; Dursun M; Canoruc F; Celik Y; Cil T; Boyraz T
J Int Med Res; 2009; 37(1):87-95. PubMed ID: 19215677
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic value of telomerase activity in differentiating benign and malignant ascitic fluid].
Yang YL; Ma ZB; Xu HY
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):745-7. PubMed ID: 16255881
[TBL] [Abstract][Full Text] [Related]
16. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions.
Abdel-Razik A; ElMahdy Y; Hanafy EE; Elhelaly R; Elzehery R; M Tawfik A; Eldars W
Am J Med Sci; 2016 Mar; 351(3):259-64. PubMed ID: 26992254
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites.
Nascimento I; Schaer R; Lemaire D; Freire S; Paule B; Carvalho S; Meyer R; Schaer-Barbosa H
APMIS; 2004 Sep; 112(9):585-7. PubMed ID: 15601306
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species modulator 1, a novel protein, combined with carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Chen X; Zhang N; Dong J; Sun G
Tumour Biol; 2017 May; 39(5):1010428317698378. PubMed ID: 28459208
[TBL] [Abstract][Full Text] [Related]
20. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
